Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 2, e15-e16 doi:10.3324/haematol.10684
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berrebi, A.
Right arrow Articles by Shvidel, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berrebi, A.
Right arrow Articles by Shvidel, L.

Online Only Articles

Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly

A. Berrebi1,*, E. Feldberg2, I. Spivak3, L. Shvidel1

1 Hematology Institute, Kaplan Medical Center, Eilat, Israel
2 Rehovot, Pathology Department, Kaplan Medical Center, Rehovot, Eilat, Israel
3 Internal Medicine Department, Yoseftal Hospital, Eilat, Israel

*Corresponding author: Alain Berrebi Hematology Institute, Kaplan Medical Center, Rehovot, Israel 76100. Tel: 972-89441383; Fax: 972-89441706; E-mail: alain_b{at}clalit.org.il

We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment

Key words: myelofibrosis, thalidomide.






HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.